Integrating pharmacists into aged care facilities to improve the quality use of medicine (PiRACF Study): Protocol for a cluster randomised controlled trial

sam kosari (sam.kosari@canberra.edu.au)  
University of Canberra  
https://orcid.org/0000-0002-6737-1442

Jane Koerner  
University of Canberra

Mark Naunton  
University of Canberra

Gregory M Peterson  
University of Tasmania

Ibrahim Haider  
University of Canberra

Emily Lancsar  
Australian National University

David Wright  
University of East Anglia

Theo Niyonsenga  
University of Canberra

Rachel Davey  
University of Canberra

Study protocol

Keywords: Residential Aged Care Facility, aged care, care home, Quality Use of Medicines, elderly, Potentially Inappropriate Medicine, pharmacists, cluster randomised controlled trial

DOI: https://doi.org/10.21203/rs.3.rs-38456/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Medication management in residential aged care facilities is an ongoing concern. Numerous studies have reported high rates of inappropriate prescribing and medication use in aged care facilities, which contribute to residents' adverse health outcomes. There is a need for new models of care that enhance interdisciplinary collaboration between residential aged care facility staff and healthcare professionals, to improve medication management. Pilot research has demonstrated the feasibility and benefits of integrating a pharmacist into the aged care facility team to improve the quality use of medicines. This protocol describes the design and methods for a cluster randomised controlled trial to evaluate the outcomes and conduct economic evaluation of a service model where on-site pharmacists are integrated into residential aged care facility healthcare teams to improve medication management.

Methods

Intervention aged care facilities will employ on-site pharmacists to work as part of their healthcare teams. Pharmacists will assume responsibility for medication management, and collaborate with facility nurses, prescribers, community pharmacists, residents and families to improve the quality use of medicines. The intervention will last for 12 months. Aged care facilities in the control group will continue usual care. The target sample size is 1,188 residents from a minimum of 13 aged care facilities. The primary outcome is the appropriateness of prescribing, measured by the proportion of residents who are prescribed at least one potentially inappropriate medicine according to the 2019 Beers Criteria. Secondary outcomes include hospital and Emergency Department presentations, fall rates, prevalence and dose of antipsychotics and benzodiazepines, Anticholinergic Cognitive Burden Score, staff influenza vaccination rate, time spent on medication rounds, appropriateness of dose form modification and completeness of resident's allergy and adverse drug reaction documentation. A cost-consequence and cost-effectiveness analysis will be embedded in the trial.

Discussion

The results of this study will provide information on clinical and economic outcomes of a model that integrates on-site pharmacists into Australian residential aged care facilities. The results will provide policymakers with recommendations relevant to further implementation of this model.

Trial registration

ACTRN: ACTRN12620000430932, retrospectively registered with ANZCTR on 1 April 2020. Available from https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primaryS

Background

Older adults residing in residential aged care facilities (RACFs) generally have complex co-morbidities and are prescribed a large number of different medications [1]. Studies have reported that, on average, RACF residents take between 9 and 11 regular medications [2–4]. Polypharmacy increases the risk of medication-related problems and adverse drug events, including hospitalisations, placing a significant burden on residents and economic cost on the health care system [5–7]. Australian studies have shown that almost all RACF residents have at least one medication-related problem [4, 8–11] and between 30% and 73% of residents are prescribed at least one potentially inappropriate medicine (PIM) [4, 12–18]. According to a recent meta-analysis of 33 international studies, the use of PIM is significantly associated with an increased risk of hospitalisation in the older population, and the risk was higher in those who took more than one PIM [19]. Additionally, PIMs are associated with other potential adverse outcomes in older individuals, including fall, fracture, cognitive decline, delirium, stroke and cardiovascular events [20, 21].

Among PIMs, sedatives, antipsychotics and drugs with anticholinergic properties are particularly associated with greater risk of harm. A large Australian cohort study among 11,368 residents found that 61% were taking psychotropic medications, with the majority of these agents having sedative properties that can contribute to falls or confusion [22]. The over-use of psychotropic medications has been recently highlighted in the interim report of the Australian Royal Commission into Aged Care Quality and Safety [23]. Australian studies have reported that over 20% of RACF residents were taking antipsychotics regularly [22, 24] and the duration of antipsychotic use was longer than recommended [25–27]. Prolonged use of antipsychotics in older people is linked with increased risk of hospitalisation, hip fracture, pneumonia, stroke and death [28, 29]. Another large Australian study [30] of 17,000 RACF residents reported that 46% were taking drugs with moderate to strong anticholinergic effects; these drugs can contribute to cognitive and functional decline, delirium, worsening dementia, and increased mortality in older people [31].

Additionally, over-prescribing, using medicines longer than recommended, and drug interactions affect medication safety in aged care residents. The Australian 2018 Aged Care National Antimicrobial Prescribing Survey reported that 10% of residents were taking an antibiotic on the day of the survey and about two-thirds of these prescriptions were lacking relevant documentation of sign and symptoms to justify the need for antibiotic use [32]. Another large Australian study reported that more than 50% of residents were prescribed proton pump inhibitors with a median duration of use of 360 days in the year, while the recommended duration of use is 8 weeks [27]. Over-prescribing can also lead to unwanted drug interactions; a retrospective study of aged care resident's medication records showed that 16% of residents were at high risk of drug-induced QT prolongation and potential arrhythmia due to polypharmacy [33]. Overall, many published studies highlight the need to improve medication management in RACFs. It is an area where pharmacists, doctors and nurses can work together, ensuring improved medication safety and quality use of medicines for residents [34].

Amongst the factors affecting medication safety and quality use of medicines in RACFs, lack of accessibility to pharmacists and doctors, and poor interdisciplinary collaboration were highlighted in a recent systematic review of international studies [35]. Consistent with these findings, the Australian Medical Association highlighted the "extremely urgent" need to increase the number of health care professionals in RACFs [36]. General practitioners (GPs),
nurses and pharmacists are the key health professionals involved in the prescribing, administration and supply of medicines. Since these health professionals are generally not co-located, there are significant limitations in access, communication [37] and coordination of medication management processes [1] for aged care residents.

In Australia, there are two government-funded pharmacist-led services in place that aim to improve medication management in RACFs: (i) residential medication management review (RMMR) program [38], and (ii) Quality Use of Medicine (QUM) service [39]. The RMMR for RACF residents has been in place since 1997 [37] and is similar to “clinical medication reviews” in the UK, “comprehensive medication reviews” in the United States and “MedsCheck LTC” in Canada [40–42]. The RMMR program enables GPs to refer RACF residents to accredited pharmacists to receive a medication review every 24 months or when there is a clinical need [43]. Although the RMMR service has been shown to be an effective strategy to identify and resolve medication-related problems and improve quality of use of medicines for RACF residents [2], the service has logistical limitations. These include physical separation of community pharmacies, RMMR pharmacists and RACFs which leads to lack of timely access to pharmacist services when residents need them most [37]. Additionally, access to clinical pharmacists to conduct RMMRs for RACF residents is limited to periodic visits to the facility. Consequently, pharmacists performing RMMRs may not have a thorough understanding of the resident and may not be familiar with the facility staff and organisational structure, resulting in limited effectiveness of their activities within RACFs. The QUM service is intended to improve the medication management at the RACF level (e.g. through audits and staff education) [39, 44], however, there has been little research to explore the effectiveness of this service [37].

Integrating an on-site pharmacist as part of the RACF health care team may address the gap in provision of medication management practices, policies and processes. The on-site pharmacist can assume overall responsibility for medication management, in collaboration with nurses, GPs, specialists and community pharmacists to ensure the quality use of medicines at the facility [45–48]. This new model can improve communication among the healthcare team and enhance resident and family’s involvement in medication management decisions for individuals [46], leading to improved person-centred care. At the facility level, the on-site pharmacist can develop and enhance RACF policies and procedures for overall medication management [49]. These system improvement activities include reviewing and enhancing medication ordering, storage and administration processes, as well as conducting staff education, providing medication information, responding to medication utilisation reports, developing clinical referral pathways and contributing to staff and resident influenza vaccination.

A proposed model of integrated on-site pharmacist services into the RACF health care team was examined in a pilot study which was conducted by the lead author [45–50]. The conceptual foundation of the new model was to improve multi-disciplinary care, communication and collaboration in RACF’s healthcare team to enhance medication management [45, 46]. The findings of the pilot study indicated that the integration of a pharmacist into a RACF was feasible and acceptable to RACF staff, residents and GPs, and resulted in improved medication administration and clinical documentation [45], increased provision of education for nursing and carer staff to promote the quality use of medicines and prevent medication administration errors [46], and enhanced staff influenza vaccination rates [47]. The positive findings of the pilot study informed the allocation of program funds from the Australian Department of Health to implement and evaluate this model in RACFs in the Australian Capital Territory (ACT).

The aim of this larger study is therefore to conduct a cluster randomised controlled trial (RCT) to evaluate if integrating pharmacists into RACFs, improves medication management in RACFs in the ACT, Australia. Objectives of the study include determining if this new integrated model (i) improves appropriateness of prescribing for RACF residents, as determined by the use of PIMs according to 2019 Beers Criteria [51], (ii) reduces RACF residents’ Emergency Department (ED) presentations and hospital admissions, (iii) improves other quality use of medicine indicators at the resident and facility levels, and (iv) is cost-effective.

Methods

Study design

This is a cluster RCT in RACFs in the ACT, Australia with RACFs as the unit of randomisation. Participating RACFs will be randomised into either an intervention or control group. RACFs in the intervention group, in addition to ‘usual care’, will each employ an on-site pharmacist as member of the healthcare team. RACFs in the control group will continue ‘usual care’ that includes receiving government funded RMMR and QUM services from visiting pharmacists. Intervention and control groups will be recruited and randomised in staggered groups which will run in parallel.

Participants

RACFs:

All RACFs in the ACT that are nationally accredited facilities will be invited to participate in the trial. RACFs that only offer respite care will be excluded.

Residents:

Permanent residents of included RACFs will be included in the study unless they specifically request their data not to be included in the trial. Respite (non-permanent) residents will be excluded.

Pharmacists:

Qualified pharmacists will be recruited through open expressions of interest sent to pharmacy professional groups and associations. The selection criteria for pharmacists include having registration with the Australian Health Practitioner Regulation Agency, accreditation to conduct medication reviews by the Australian Association of Consultant Pharmacy or equivalent hospital or geriatric clinical pharmacy experience, and accreditation to conduct vaccination. A list of eligible pharmacists will be provided to the intervention RACFs, who will employ pharmacists as per their organisational policy. Salaries for pharmacists will be funded by the research grant; however, they will be directly employed by RACFs as RACF staff members.
Pharmacist activities in intervention RACFs include:

- Performing medication reviews in collaboration with residents, families, prescribers and nurses
- Identifying residents at high risk of medication-related harm and hospitalisation, and prioritising interventions to address them
- Medication reconciliation and review at transition of care
- Reviewing and optimising medication administration rounds
- Updating and improving resident records including clinical and care information
- Answering medication-related queries from residents, families and staff
- Conducting regular clinical audits to identify medication-related problems
- Educating residents, families and RACF staff about medications related issues
- Improving the RACF’s medication management policies and procedures

Recruitment process

All RACFs in the ACT, Australia that meet the inclusion criteria will be invited to participate in this study. After being provided information on the nature of the study and data required, each RACF will agree to participate through a signed contract. Recruitment will be staggered over a period of 6 months or until the sample size achieved. The recruitment and study timelines are shown in Fig. 1.

Randomisation and blinding

Randomisation will be at the facility level. RACFs will be randomised into either intervention or control group through computer-generated allocation by an independent researcher external to the research team. Randomisation will be stratified by size of facility. Due to the nature of the intervention, the trial participants will not be blinded.

Intervention and model of care

RACFs in the intervention arm will have a pharmacist employed by their organisation as part of their health care team for 2 to 2.5 days a week for 12 months. Pharmacists will report to RACF managers. They will conduct resident and facility level activities that are within their current scope of practice as a health professional registered with Australian Health Professional Registered Agency.

The intervention (model of care) was informed by the findings from the pilot study [45–50] and discussion with RACF managers, GPs, pharmacists and a consumer representative who participated in the pilot. Components of this model of care are informed by integration of pharmacists into non-dispensing primary care roles [52, 53]. Components and how they differ from usual care are presented in Table 1.

| Key component                        | Existing model                                                                 | Proposed model                                                                 |
|--------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Governance and service structure     | RMMR & QUM activities are conducted by independent pharmacist (who are contractors) on visitational basis. | Pharmacist is employed by the RACF and is incorporated into RACFs care team. Pharmacist works within RACFs clinical governance structures. |
| Multi-disciplinary care (including resident and family) | Pharmacist is not incorporated into the RACF care team. They visit RACF at semi-regular intervals, provide medication advice to GPs through RMMRs and provide quality improvement projects. | Pharmacist is incorporated into the RACF care team and has contact with residents, families, GPs and prescribers, nurses and care staff. The pharmacist is available on-site at RACFs and involves residents and families into decision-making processes to improve medication management. |
| Reciprocal interdependence           | Pharmacist provides medication review as an add-on service to assist GPs with quality of prescribing. However, they are not incorporated into the RACF care teams. | Multi-disciplinary team members, including pharmacists, nurses, carers, GPs and prescribers, community pharmacists, residents and families engage in shared decision making and work together to achieve goals. |
| Communication                        | Pharmacist communicates medication-related issues about individual residents to the GPs, usually through RMMR. GPs communicate medication changes to RACF nurses. | Pharmacist communicates and coordinates medication-related issues directly with GPs, nurses, carers, residents, community pharmacy and hospital. |
| Collaboration                        | Pharmacist usually collaborates with GPs to conduct RMMR. | Pharmacist closely collaborates on a regular basis with nurses, aged care staff and management, GPs and other prescribers, visiting pharmacists, community pharmacy, residents, families and hospital. |
| Sharing and access to information    | Pharmacist has limited access to residents’ clinical records, which may include laboratory reports, while GPs and nurses have full access to clinical records. | All team members, including the pharmacist, will have full access to residents’ records, current medication lists, information about allergies, lab results, notes, procedures, and hospital discharge summaries. |
| Coordinated care/outcomes           | Pharmacist provides once-off advice and opinion to GPs in RMMRs (including 2 follow-ups) but are not involved in implementing medication management changes or ongoing monitoring. | Residents’ treatment goals and outcomes are coordinated within the team of nurses, carers, pharmacist, GPs and other service providers. Pharmacist is involved in providing advice to GPs, prescribers and the RACF care team, and in implementing residents care plans and goals of care. Pharmacist also contributes to improving RACF medication management policies and procedures. |
• Improving influenza vaccination rates of staff and residents

Pharmacist training and support

Pharmacists will participate in mandatory training before commencing in RACFs, including an initial full-day overview of clinical pharmacy practice in the aged care setting, followed by a session focused on the pharmacist’s role in RACFs and the trial design and processes. Pharmacists will be provided with clinical and geriatric pharmacy resources including content on deprescribing, psychotropics, pain management, principles of medication review in aged care, Beers Criteria [51] and wound management.

The study team will meet face to face with pharmacists monthly to discuss potential problems and address questions. Furthermore, pharmacists will be invited to participate in quarterly meetings held by the study team to discuss study activities. An online Microsoft Teams will link on-site pharmacists to each other to facilitate a community of learning to discuss issues they are experiencing.

Outcomes

All outcome measures will be collected from both intervention and control RACFs and compared as below.

Primary outcome

• Change in proportion of residents who are prescribed at least one PIM (from baseline to 12-months) according to the 2019 Beers Criteria [51]

Secondary outcomes

• Rate of ED presentations and hospital admissions per resident collected from RACF records over 12 months
• Change in proportion of residents who are prescribed at least one psychotropic medicine (defined as antipsychotics and benzodiazepines), excluding those residents with major psychiatric diseases or epilepsy (from baseline to 12-months)
• Change in dose of psychotropic medicines (measured as chlorpromazine or diazepam equivalent daily dose [54] (from baseline to 12-months)
• Change in residents’ Anticholinergic Cognitive Burden Score (ACB) [55] (from baseline to 12-months)
• Rate of staff influenza vaccination measured at the end of influenza season, from RACF records
• Fall rate per resident, as documented from RACF fall records over 12 months
• Change in time spent on medication administration rounds per RACF, through observing randomly selected medication rounds [45] (from baseline to 12-months)
• Change in appropriateness of medicine dose form modification per RACF, through observing randomly selected medication rounds [45] (from baseline to 12-months)
• Change in proportion of residents who have drug allergies or adverse drug reactions documented in their RACF records (from baseline to 12-months)
• Number of medication-related incidents over 12 months
• Cost-consequence and cost-effectiveness of the intervention over 12 months

Data collection

Data will be collected at RACF, resident and pharmacist levels throughout the 12-month trial period. RACFs’ characteristics (number of beds, number of permanent residents, resident profile and number of staff) will be collected through surveys with RACF managers. De-identified residents’ data for outcome measures will be collected by the research team visiting the facilities at baseline, each month and at 12 months. Randomly selected medication rounds will be observed to determine the time spent on medication rounds and assess the appropriateness of dose form modifications using the method described earlier [45]. In case of potential logistical limitations in light of COVID-19 and any future restriction of access to RACFs, RACF staff will collect the required data. On-site pharmacists in the intervention group will self-report their daily activities through an online diary using QUALTRICS. Details of data collection items and timing are listed in Table 2.

Page 5/11
### Table 2
Data collection details

| Data                                                                 | Data collection              |
|----------------------------------------------------------------------|------------------------------|
| **Facility level data**                                             |                              |
| Number of permanent residents, proportion of residents with dementia, and proportion receiving the highest level of government funding | Baseline and at 12 months    |
| Number of RACF registered nurses rostered during day/night/weekend   | Baseline and at 12 months    |
| Care staff turn-over reported by RACFs                               | Baseline                     |
| Total number of beds and bed occupancy rate                          | Monthly                      |
| Resident turnover                                                   | Monthly                      |
| Number of medication-related incidents                              | Monthly                      |
| Number of resident falls                                           | Monthly                      |
| Time taken to conduct medication rounds                             | Baseline and at 12 months    |
| % of staff/residents received influenza vaccination                  | At one time point             |
| % of residents that have drug allergy and adverse drug reactions documented | Baseline and at 12 months    |
| Number of GPs visiting residents in facility                        | Baseline                     |
| RACF managers perceived top 5 reasons for unplanned hospitalisations of residents in previous 12 months, and possible solutions for reducing these | Baseline                     |
| **Resident level data**                                             |                              |
| Age and gender                                                      | Baseline                     |
| Date of admission and discharge and reason for discharge from the facility | Baseline and monthly          |
| Diagnosis                                                           |                              |
| Number and list of regular and PRN medications including dosages    | Baseline and at 12 months    |
| Emergency Department visit/transfer*                                | Baseline and monthly         |
| Hospital admissions* and length of hospital stay as determined by RACF residents’ records | Baseline and monthly         |
| Reason for Emergency Department visit/admission to hospital - as determined by RACF residents’ records | Baseline and monthly         |
| **Intervention pharmacist activity data**                           |                              |
| Daily activities and time taken to conduct each activity             | Daily                        |

*Outpatient appointments & scheduled procedures will not be included in hospital admission/Emergency Department visit data.

### Sample size

It was estimated that a conventional RCT with randomisation of individuals would be able to detect a reduction from 60–40% of residents having at least one PIM, with a minimum of 106 residents in each arm (total of 212 residents in both arms) with a significance level of 5%, a power of 80% on equal allocation and a response rate of 85%. By adjusting for the loss of power due to clustering, with an intra-cluster correlation coefficient of 0.05 and a cluster size of 93 residents per RACF, the estimated sample size is \(1 + \left(93-1 \times 0.05\right) = 5.6 \times 106\) or 594 residents in each arm (1188 in both arms), equating to a minimum of 13 sites. The sample size was calculated using G*Power 3.1.9.4 [56].

The estimated prevalence of PIM in RACFs at baseline (60%) was based on previous studies in which the prevalence of PIM in Australian RACF residents were reported as 73% in 2018 [16], 49% in 2014 [14] and 56% in 2012 [57].

### Data management

De-identified data will be collected from RACFs, by research staff. RACF staff will facilitate the collection of data from RACF digital and paper records. Collection of data will be onto a university laptop which is password-protected. Resident’s identifying details (e.g. names and date of birth) will not be collected for analysis. Residents will be given a unique study identifier to link data that will be stored in a secure place at the RACF. Data will be entered onto a central database developed with Microsoft Access and stored on the University of Canberra secure and password-protected data storage system. Access to the database will be by the key members of the research team with unique usernames and passwords. The servers are protected by firewalls and are maintained according to best practice. After the completion of the study, the database will remain on the university storage system for 5 years, as per National Health and Medical Research Council (NHMRC) guidelines.
Statistical analysis

Descriptive statistics will be used to summarise and compare the data at the RACF level in each group at baseline and at the end of the trial, including primary and secondary outcomes as well as additional potential confounder variables (such as demographic profile, duration of residency, presence of dementia, Charlson comorbidity index [58] and number of medical conditions).

Bivariate analyses for group comparisons will use either t-tests or ANOVA for data that are normally distributed, Mann-Whitney U and Kruskall-Wallis tests for data that are not normally distributed, or Chi-square based analysis for categorical outcome data. For within group comparisons, paired t-tests and repeated measures ANOVAs will be used; if variables are not normally distributed, the Wilcoxon Signed Ranks and Freedman tests will be used, while the McNemar test will be used for changes in proportions.

To determine the effect of the intervention on the outcome measures and the changes over time (between-within group effects), multilevel modelling methods, which take into consideration the hierarchical structure of the data (including clustering within RACF and repeated measurement occasions) will be applied. These modelling methods will include mixed-effects generalised linear models ( Logistic and Poisson regression models) for binary and count outcomes as well as mixed-effects linear models for continuous outcomes assumed to have a normal distribution, or otherwise transformed to meet the assumption.

Analysis will be weighted by cluster size as required. Interactions and adjusting for demographic characteristics and other potential covariates will be included when deemed necessary. Residents who enter, die or move from RACFs after baseline data collection will have only one data point and will be included in the analysis. When data are missing at random, patterns of missing data will be evaluated, and potential predictors of missing responses will be investigated. Methodological attempts to fill in missing data will be extensively explored and applied as appropriate. These include single imputation approaches (such as regression imputation and nearest neighbours or hot-deck imputation) and multiple imputation approaches. Analysis will be conducted using either SPSS version 26 or STATA version 16. Significance level will be set at the usual 5% alpha-level (two-tailed where applicable). All estimated effects will be reported along with their 95% confidence intervals.

Since the sample size and power calculation have been devised based on the primary outcome and hypothesis, the level of adjustment and number of potential covariates to adjust for, may be limited by the sample size and the response rate. Posterior power calculations will be performed based on available sample size and the secondary outcomes.

Economic evaluation

A within trial cost consequence followed by a cost effectiveness analysis will be conducted. The cost consequence analysis will explore the incremental impact (compared to the control arm) of the intervention on the disparate secondary outcomes, providing more information to decision makers in addition to a having a focus on the primary outcome. For the cost effectiveness analysis, effectiveness will be measured in terms of the primary outcome - avoided PIM (reduction of the number of residents who take at least one PIM). A public health sector perspective will be used. All resource use will be valued in 2020/21 Australian dollars without discounting. Total costs for the intervention and control groups will be calculated, as well as average costs per participant, incorporating any additional costs relating to the delivery of the intervention (e.g. additional training, time that a GP spends on reviewing pharmacist recommendations). Resource use captured during the trial will include health service utilisation by each participant (ED visits, hospital admissions, ambulance transfer during the 12 months of control/intervention period; and medications used at baseline and at 12-months). Analogous multilevel modelling described above (controlling for differences in characteristics of participants and RACF clusters) will be used to estimate average cost per participant for both intervention and control groups. An incremental cost-effectiveness ratio (ICER) will be computed by comparing the costs and outcomes of the intervention and control groups. Results will be expressed as incremental cost per incremental reduction in the proportion of residents taking at least one PIM. Mean estimates will be used, and confidence values and sensitivity analysis will indicate the robustness and validity of the results and test any assumptions used. Uncertainty around the ICER will be explored using cost-effectiveness acceptability curves.

Fidelity assessment

Fidelity in intervention sites will be assessed using Hasson's Conceptual Framework [59], that assesses adherence against content, coverage, frequency and duration domains at the cluster level. First, 100% of pharmacist diaries in each intervention RACF will be assessed and cumulative number and proportion of activities will be calculated. Second, a random sample of 10% of resident's medications reviews conducted by intervention pharmacists will be assessed by an experienced pharmacist to determine the appropriateness of medication reviews. Third, interviews with RACF managers, staff and pharmacists will further explore adherence to the trial activities. Intervention RACFs will be given a fidelity rating of high/medium/low based on the assessment.

Trial management

The trial is overseen by the trial management group comprising chief investigators and the senior programme manager. The trial is advised by the governance committee organised by the funder, the ACT Primary Health Network (PHN) and comprises representative from RACFs, Pharmaceutical Society of Australian, Pharmacy Guild of Australia, Calvary hospital, a GP and a consumer representative. Potential protocol modifications by the trial management group will be communicated to the governance committee and human research ethics committees.

Safety evaluation and reporting

Criteria for monitoring the trial are informed by Stallard [60], whereby adverse events will be monitored and the trial ceased if there is evidence of harm. All adverse events will be entered into an Adverse Event Log and reported to external clinical consultants to determine whether or not they are considered causally related to study. For every adverse event, researchers and external consultants will provide an assessment of the severity, causal relationship to the study, outcomes and seriousness of the event, and document all actions and inform the Human Research Ethics Committee. In light of the COVID-19 pandemic, the research team will follow all RACF's safety protocols and guidelines when they visit RACFs to ensure the safety of the residents and RACF staff.
Discussion

The initial pilot study [45-50] confirmed the feasibility of the model and no adverse events were identified. This is the first cluster RCT to our knowledge, that investigates the effectiveness of integrating pharmacists in RACFs on improving medication management. The primary outcome is the appropriateness of prescribing, that in a broader sense may represent an ideal for care [61]. Inappropriate prescribing has become an important public health concern worldwide [62] and is also prevalent in Australian RACFs [14, 16, 57]. In this trial, appropriateness of prescribing is measured using explicit Beers Criteria [51] which can be readily applied to a large sample of study participants with a high level of reliability and reproducibility [62]. Secondary outcomes include measures such as hospital admission and ED visit that are important from the public health, aged care industry and resident perspectives.

Medication management for older residents in RACFs is sub-optimal [4]. International evidence has demonstrated that pharmacist-led interventions in RACFs improve the quality use of medicines, however, the majority of these interventions were conducted by visiting pharmacists on once-off or limited visitation basis [34, 63]. There is a need for sustainable interventions to enable system level improvement in medication management practices in RACFs.

The study is using a staggered approach to the recruitment and intervention. Due to the impact of the recent COVID-19 pandemic on RACF’s workforce and operations, this staggering will provide the facilities with time to prepare and adapt to recent policy and procedural changes. These changes may impact on the study outcomes; for example, there may be changes in the number of regular healthcare staff in RACFs or residents may receive fewer GP and other visiting healthcare professional visits and this may impact the level of collaboration with pharmacists. Potential restrictions in visiting RACFs due to COVID-19 pandemic may affect the data collection processes. On-site pharmacists participating in this study will have accreditation to conduct medication review; however, they may be at different level of experience and skills, which may impact the quality of pharmacist activities in some RACFs; This will be further explored by assessing the fidelity of interventions that determines whether the intervention was conducted as planned across the intervention RACFs and includes an audit on the appropriateness of pharmacists’ medication reviews. Participating RACFs will be all within ACT which is a metropolitan area in Australia, thus the findings may not be generalisable to RACFs located in rural and remote areas.

The study provides important information on clinical and economical outcomes of the model where on-site pharmacists are integrated into RACFs’ health care team to improve medication management. The results will provide policymakers with recommendations relevant to the potential further implementation of this model.

Trial status

The study is being conducted according to the trial protocol version 3 revised on 7/4/2020. Recruitment began on 28 Oct 2019 and is anticipated to be completed by 1 July 2020.

Abbreviations

RACF
Residential Aged Care Facility
PIM
Potentially Inappropriate Medication
RMMR
Residential Medication Management Review
GP
General Practitioner
QUM
Quality Use of Medicines
RCT
Randomised Controlled Trial
ED
Emergency Department
ICER
Incremental Cost-Effectiveness Ratio
NHMRC
National Health and Medical Research Council

Declarations

Ethics approval and consent to participate

The trial is approved by the University of Canberra (HERC:2007), ACT Health (2019/ETH13453) and Calvary Public Hospital Bruce Human Research Ethics Committees (30-2019). The study will be conducted in compliance with NHMRC guidelines [64], the World Medical Declaration of Helsinki [65] and all amendments. The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) (ACTRN: ACTRN12620000430932) on 1 April 2020.

Consent to participate will be gained at the facility level, rather than resident level, given the impracticalities of gaining informed consent from a large population (estimated > 1,500 people), many of whom are likely to have cognitive impairment; there is a low risk to participants and actions will be taken to
protect of participant of privacy. This consent process follows Australian NHMRC guidelines [64] and is consistent with comparable studies conducted in Australia [66, 67].

**Consent for publication**

No individual identifiable person's data is included in this manuscript or will be included in the future publications of the main trial results. Study findings will present aggregated resident data and will not include personal identifying details. A summary of study findings will be made available to participants.

**Availability of data and materials**

The trial dataset will not be made publicly available. Only investigators have access to the trial dataset.

**Competing interests**

SK and MN are pharmacists who provide clinical consulting services to some RACFs in the ACT. Other authors have no competing interests.

**Funding**

The study is funded by the ACT PHN through the Australian Government's PHN Program. The funder is given opportunity to provide feedback but does not have ultimate authority over the study design, data collection and management, analysis, and interpretation of data, writing of the report, and the decision to submit the report for publication.

**Authors contribution**

All authors contributed to the design of the study and writing of the manuscript. All authors confirm their eligibility as authors and involvement in this study.

**Acknowledgements**

Authors would like to acknowledge the Capital Health Network, project governance committee, the Australian Department of Health, and aged care facility staff, residents and families.

**References**

1. Kosari S, McDerby N, Thomas J, Naunton M. Quality use of medicines in aged care facilities: A need for new models of care. J Clin Pharm Ther. 2018;43:591–3.
2. Chen EYH, Wang KN, Sluggett JK, Ilomaki J, Hilmer SN, Corlis M, et al. Process, impact and outcomes of medication review in Australian residential aged care facilities: A systematic review. Australas J Ageing. 2019;38(Suppl 2):9–25.
3. Roughhead EE, Gilbert AL, Woodward MC. Medication Use by Australian War Veterans in Residential Aged-Care Facilities. J Clin Pharm Ther. 2008;38:14–8.
4. Pharmaceutical society of Australia. Medicine Safety: Aged Care. PSA. 2020. https://www.psa.org.au/wp-content/uploads/2020/02/Medicine-Safety-Aged-Care-RES1.pdf. Accessed 12 Apr 2020.
5. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28:173–86.
6. Hajjar ER, Caferio AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.
7. Pharmaceutical Society of Australia. Medicine Safety: Take Care. PSA. 2019. https://www.psa.org.au/wp-content/uploads/2019/01/PSA-Medicine-Safety-Report.pdf. Accessed 15 May 2020.
8. Stafford AC, Tenni PC, Peterson GM, Jackson SL, Hejlesen A, Villesen C, et al. Drug-related problems identified in medication reviews by Australian pharmacists. Pharm World Sci. 2009;31:216–23.
9. Nishtala PS, McLachlan AJ, Bell JS, Chen TF. A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. J Eval Clin Pract. 2011;17(1):97–103.
10. Kaur S, Roberts JA, Roberts MS. Evaluation of medication-related problems in medication reviews: a comparative perspective. Ann Pharmacother. 2012;46:972–82.
11. Gheewala PA, Peterson GM, Curtin CM, Nishtala PS, Hannan PJ, Castelino RL. Impact of the pharmacist medication review services on drug-related problems and potentially inappropriate prescribing of renally cleared medications in residents of aged care facilities. Drugs Aging. 2014;31:825–35.
12. Moyle W, El Saifi N, Draper B, Jones C, Beattie E, Shum D, et al. Pharmacotherapy of Persons with Dementia in Long-Term Care in Australia: A Descriptive Audit of Central Nervous System Medications. Curr Drug Saf. 2017;12:95–102.
13. Price SD, Holman CD, Sanfilippo FM, Emery JD. Are high-care nursing home residents at greater risk of unplanned hospital admission than other elderly patients when exposed to Beers potentially inappropriate medications? Geriatr Gerontol Int. 2014;14:934–41.
14. Poudel A, Peel NM, Nissen L, Mitchell C, Gray LC, Hubbard RE. Potentially inappropriate prescribing in older patients discharged from acute care hospitals to residential aged care facilities. Ann Pharmacother. 2014;48:1425–33.
15. Somers M, Rose E, Simmonds D, Whitelaw C, Calver J, Beer C. Quality use of medicines in residential aged care. Aust Fam Physician. 2010;39:413–6.
16. Harrison SL, Kouladjian O'Donnell L, Bradley CE, Milte R, Dyer SM, Gnanamanickam ES, et al. Associations between the Drug Burden Index, Potentially Inappropriate Medications and Quality of Life in Residential Aged Care. Drugs Aging. 2018;35:83–91.
17. Stafford AC, Alswayan MS, Tenni PC. Inappropriate prescribing in older residents of Australian care homes. J Clin Pharm Ther. 2011;36:33–44.
18. Disalvo D, Luckett T, Luscombe G, Bennett A, Davidson P, Chenoweth L, et al. Potentially Inappropriate Prescribing in Australian Nursing Home Residents with Advanced Dementia: A Substudy of the IDEAL Study. J Palliat Med. 2018;21:1472–9.
19. Xing XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations Between Potentially Inappropriate Medications and Adverse Health Outcomes in the Elderly: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019;53:1005–19.
20. Fick DM, Mion LC, Beers MH, Waller L. J. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health. 2008;31:42–51.
21. Ni Chroinin D, Neto HM, Xiao D, Sandhu A, Brazel C, Farnham N, et al. Potentially inappropriate medications (PIMs) in older hospital in-patients: Prevalence, contribution to hospital admission and documentation of rationale for continuation. Australas J Ageing. 2016;35:262–5.
22. Westbury J, Gee P, Ling T, Kitsos A, Peterson G. More action needed: Psychotropic prescribing in Australian residential aged care. Aust N Z J Psychiatry. 2019;53:136–47.
23. Royal Commission into Aged Care Quality and Safety. Interim Report. 2019. https://agedcare.rcqcs.gov.au/publications/Pages/interim-report.aspx. Accessed 4 Mar 2020.
24. Pont LG, Raban MZ, Jorgensen ML, Georgiou A, Westbrook JI. Leveraging new information technology to monitor medicine use in 71 residential aged care facilities: variation in polypharmacy and antipsychotic use. Int J Qual Health Care. 2018;30:810–6.
25. Lind KE, Raban MZ, Georgiou A, Westbrook JI. Duration of Antipsychotic Medication Use by Aged Care Facility Residents With Dementia. Alzheimer Dis Assoc Disord. 2019;33:331–8.
26. Shin HY, Gadjzhanova S, Roughhead EE, Ward MB, Pont LG. The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. Int Psychogeriatr. 2016;28:977–82.
27. Kalisch Elliott LM, Kassie GM, Pratt NL, Kerr M, Roughhead EE. Prevalence and Duration of Use of Medicines Recommended for Short-Term Use in Aged Care Facility Residents. Pharmacy (Basel). 2019;7:55.
28. Pratt N, Roughhead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011;34:567–75.
29. Pratt N, Roughhead EE, Ryan P, Salter A. Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiol Drug Saf. 2010;19:699–707.
30. Hillen JB, Vitry A, Caughey GE. Medication-related quality of care in residential aged care: an Australian experience. Int J Qual Health Care. 2019;31:298–306.
31. Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76:319–35.
32. Australian Commission on Safety and Quality in Health Care. Aged Care National Antimicrobial Prescribing Survey Report. 2019. https://www.safetyandquality.gov.au/sites/default/files/2019-10/2018_ac_naps_report.pdf. Accessed 25 Apr 2020.
33. Christensen L, Turner JR, Peterson GM, Naunton M, Thomas J, Yee KC, et al. Identification of Risk of QT Prolongation by Pharmacists When Conducting Medication Reviews in Residential Aged Care Settings: A Missed Opportunity? J Clin Med. 2019;8:1866.
34. Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016. doi:10.1002/14651858.CD009095.
35. Al-Jumaili AA, Doucette WR. Comprehensive Literature Review of Factors Influencing Medication Safety in Nursing Homes: Using a Systems Model. J Am Med Dir Assoc. 2017;18:470–88.
36. Australian Medical Association. Aged Care Survey Report. 2017. https://ama.com.au/system/tdf/documents/2017%20AMA%20Aged%20Care%20Survey%20Report.pdf?file=1&type=node&id=48948. Accessed 22 Mar 2020.
37. Sluggett JK, Ilomaki J, Seaman KL, Corlis M, Bell JS. Medication management policy, practice and research in Australian residential aged care: Current and future directions. Pharmacol Res. 2017;116:20–8.
38. Gilbert AL, Roughhead EE, Beilby J, Mott K, Barratt JD. Collaborative medication management services: improving patient care. Med J Aust. 2002;177:189–92.
39. Pharmaceutical Society of Australia. Guidelines for pharmacists providing Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) services. 2017. https://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-RMMR-and-QUM-Guidelines.pdf. Accessed 01 Jan 2020.
40. Pellegrino AN, Martin MT, Tilton JJ, Touchette DR. Medication therapy management services: definitions and outcomes. Drugs. 2009;69:393–406.
41. Houle SK, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services. Can Pharm J (Ott). 2014;147:209–32.
42. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74:573–80.
43. Chen TF. Pharmacist-Led Home Medicines Review and Residential Medication Management Review: The Australian Model. Drugs Aging. 2016;33:199–204.
44. Department of Health and Ageing: Australian Government. Guiding principles for medication management in residential aged care facilities. 2012. https://www.health.gov.au/sites/default/files/documents/2020/02/guiding-principles-for-medication-management-in-residential-aged-care-facilities.pdf. Accessed 06 Feb 2020.
45. McDerby N, Kosari S, Bail K, Shield A, Peterson G, Naunton M. The effect of a residential care pharmacist on medication administration practices in aged care: A controlled trial. J Clin Pharm Ther. 2019;44:595–602.

46. McDerby N, Kosari S, Bail KS, Shield AJ, Thorpe R, Naunton M. Residential care pharmacists: another hole plugged in the Swiss cheese. J Pharm Pract. 2019;49:84–9.

47. McDerby NC, Kosari S, Bail KS, Shield AJ, MacLeod T, Peterson GM, et al. Pharmacist-led influenza vaccination services in residential aged care homes: A pilot study. Australas J Ageing. 2019;38:132–5.

48. McDerby N, Kosari S, Bail K, Peterson G, Naunton M. Residential Aged Care Pharmacist: An Australian Pilot Trial Exploring the Impact on Quality Use of Medicines Indicators. Medicines (Basel). 2020;7:20.

49. McDerby N, Naunton M, Shield A, Bail K, Kosari S. Feasibility of Integrating Residential Care Pharmacists into Aged Care Homes to Improve Quality Use of Medicines: Study Protocol for a Non-Randomised Controlled Pilot Trial. Int J Environ Res Public Health. 2018;15:499.

50. McDerby N, Kosari S, Bail KS, Shield AJ, Peterson G, Thorpe R, Naunton M. The role of a residential aged care pharmacist: Findings from a pilot study. Australas J Ageing. 2020. doi:10.1111/ajag.12784.

51. American Geriatrics Society Beers Criteria® Update Expert Panel. Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94.

52. Hazen AC, De Bont AA, Boelman L, Zwart DL, De Gier JJ, De Wit NJ, Bouvy ML. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: A systematic review. Res Social Adm Pharm. 2018;14:228–40.

53. Sluggett JK, Ilomäki J, Seaman KL, Corlis M, Bell JS. Medication management policy, practice and research in Australian residential aged care: current and future directions. Pharmacol Res. 2017;116:20–8.

54. Drug and Alcohol Services South Australia. Benzodiazepines: information for GPs. 2018. https://www.sahealth.sa.gov.au/wps/wcm/connect/dbd6d500407749f193d6bb222b2948cf/Benzodiazepines+-+GPs-DASSA-August2014.pdf?MOD=AJPERES. Accessed Jan 08 2020.

55. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.

56. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60.

57. Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dement Geriatr Cogn Dis Extra. 2012;2:361–71.

58. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries. Am J Epidemiol. 2011;173:676–82.

59. Hasson H, Blomberg S, Dunér A. Fidelity and moderating factors in complex interventions: a case study of a continuum of care program for frail elderly people in health and social care. Implement Sci. 2012;7:23.

60. Stallard N, Whitehead J, Todd S, Whitehead A. Stopping rules for phase II studies. Br J Clin Pharmacol. 2001;51:523–9.

61. Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SN. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review. J Am Geriatr Soc. 2011;59:1521–30.

62. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? The Lancet. 2007;370:173–84.

63. Lee SWH, Mak VSL, Tang YW. Pharmacist services in nursing homes: A systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85:2668–88. https://doi.org/10.1111/bcp.14101.

64. National Health and Medical Research Council. National statement on ethical conduct in human research 2007. (Updated 2018). 2018. https://www.nhmrc.gov.au/about-us/publications/national-statement-ethical-conduct-human-research-2007-updated-2018. Accessed 12 Dec 2019.

65. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–8.

66. Liu W, Koerner J, Lam L, Johnston N, Samara J, Chapman M, Forbat L. Improved quality of death and dying in care homes: a palliative care stepped wedge randomised control trial in Australia. J Am Geriatr Soc. 2020;68:305–12.

67. Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208:398–403.